Home›Stock Screener›Sai Life Sciences›Financial Statements

Sai Life Sciences Complete Financial Statements

8 Years of Data
2026 - 2019

In FY2026, Sai Life Sciences (SAILIFE) reported revenue ₹618 Cr, net profit ₹104 Cr and EPS ₹4.93, with a net profit margin of 16.8% and ROE of 4.2%. Full financial statements from FY2019 to FY2026 (8 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review SAILIFE earnings valuation to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 16.83% 2026 data
EBITDA Margin 31.07% 2026 data
Operating Margin 29.00% 2026 data
Return on Assets 2.87% 2026 data
Return on Equity 4.19% 2026 data

Balance Sheet Ratios

Current Ratio 4.57 2026 data
Equity Ratio 68.51% 2026 data
Asset Turnover 0.17 2026 data

SAILIFE Revenue, Net Profit & EBITDA — Year-on-Year Growth

SAILIFE YoY (Mar 2025 vs Mar 2026) — revenue +4.9%, net profit +18.2%, EBITDA +15.0%, expenses +0.9%. For live price, earnings ratios and company overview, see Sai Life Sciences share price screener.

Revenue Growth
+4.9%
Year-over-Year
Net Profit Growth
+18.2%
Year-over-Year
EBITDA Growth
+15.0%
Year-over-Year
Expense Growth
+0.9%
Year-over-Year
Assets Growth
+14.7%
Year-over-Year
Equity Growth
+16.7%
Year-over-Year
Operating Cash Flow Growth
+19.4%
Year-over-Year
Investing Cash Flow Growth
-180.6%
Year-over-Year
Financing Cash Flow Growth
+416.8%
Year-over-Year

SAILIFE Income Statement — Revenue, EBITDA & Net Profit

Sai Life Sciences revenue ₹618 Cr, EBITDA ₹192 Cr, net profit ₹104 Cr, EPS ₹4.93 (2026) — net profit margin 16.8%. Explore Sai Life Sciences intrinsic worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Dec 2023
Revenue 618 553 589 506 565 406 443 288 449 395
Expenses 426 392 422 376 377 293 315 254 320 287
EBITDA 192 161 167 131 188 112 128 34 129 108
Operating Profit Margin % 29.00% 27.00% 27.00% 24.00% 32.00% 26.00% 28.00% 9.00% 27.00% 25.00%
Depreciation 45 40 38 38 44 36 31 31 34 31
Interest 8 9 11 12 10 21 21 21 23 23
Profit Before Tax 139 112 119 81 134 55 76 -18 72 53
Tax 35 28 31 20 34 14 20 -5 18 13
Net Profit 104 84 88 61 100 42 56 -14 54 40
Earnings Per Share (₹) 4.93 4.01 4.24 2.90 4.77 2.22 31.00 -0.74 2.89 2.19

SAILIFE Balance Sheet — Assets, Liabilities & Shareholders' Equity

SAILIFE total assets ₹3,626 Cr, total equity ₹2,484 Cr, total liabilities ₹ Cr (2026) — ROE 4.2%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019
ASSETS
Total Assets 3,626 3,160 2,275 2,187 2,157 1,817 1,410 1,216
Current Assets 1,411 1,505 945 964 944 804 613 691
Fixed Assets 2,085 1,488 1,180 1,037 751 701 641 374
Capital Work in Progress 271 125 107 151 410 246 91 116
Investments 151 2 2 2 0 0 0 0
Other Assets 0 1,545 987 997 997 870 679 726
LIABILITIES
Total Liabilities
Current Liabilities 309 299 560 540 565 356 149 160
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 2,484 2,128 975 888 879 863 794 720
Share Capital 21 21 18 18 18 18 16 16
Reserves & Surplus 2,463 2,108 957 870 861 845 777 703

SAILIFE Cash Flow Statement — Operating, Investing & Financing

Sai Life Sciences operating cash flow ₹314 Cr, investing ₹-536 Cr, financing ₹301 Cr, net cash flow ₹79 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019
Operating Activities 314 263 219 105 -36 116 129
Investing Activities -536 -191 -99 -102 -260 -262 -158
Financing Activities 301 -95 -201 72 296 -4 268
Net Cash Flow 79 -24 -80 75 -1 -150 239